SCHEMBL12225936

SCHEMBL12225936

Clc1cccc(I)c1NC1=NCCN1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 13/20 0.79
ADRA2B P18089 8/20 0.79
ADRA2C P18825 8/20 0.79
LMNA P02545 4/20 0.79
ADRA1A P35348 4/20 0.79
NISCH Q9Y2I1 4/20 0.79
ADRA1D P25100 3/20 0.79
ADRA1B P35368 3/20 0.79
CYP2D6 P10635 2/20 0.79
HRH2 P25021 2/20 0.79
MEN1 O00255 1/20 0.79
SLC22A1 O15245 1/20 0.79
SLC22A3 O75751 1/20 0.79
HTR1A P08908 1/20 0.79
CYP2C9 P11712 1/20 0.79
CYP2C19 P33261 1/20 0.79
OPRK1 P41145 1/20 0.79
KMT2A Q03164 1/20 0.79
HIF1A Q16665 1/20 0.79
SLC47A1 Q96FL8 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clonidine SCHEMBL5983 0.89 ADRA2A (1.00) ADRA2AADRA2BADRA2CLMNAADRA1A
SCHEMBL29374579 0.89 ADRA2C (0.65) ADRA2AADRA2BADRA2CLMNAADRA1A
Clonidine SCHEMBL9838990 0.87 ADRA2A (0.97) ADRA2AADRA2BADRA2CLMNAADRA1A
Clonidine SCHEMBL2231324 0.87 ADRA2A (1.00) ADRA2AADRA2BADRA2CLMNAADRA1A
Clonidine SCHEMBL40752 0.87 ADRA2A (1.00) ADRA2AADRA2BADRA2CLMNAADRA1A
Clonidine SCHEMBL613364 0.87 ADRA2A (0.97) ADRA2AADRA2BADRA2CLMNAADRA1A
SCHEMBL9920135 0.82 ADRA2A (0.79) ADRA2AADRA2BADRA2CLMNAADRA1A
SCHEMBL11176814 0.82 ADRA2A (0.79) ADRA2AADRA2BADRA2CLMNAADRA1A
Clonidine SCHEMBL18050245 0.81 ADRA2A (0.82) ADRA2AADRA2BADRA2CLMNAADRA1A
SCHEMBL29352531 0.80 ADRA2A (0.81) ADRA2AADRA2BADRA2CLMNAADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110245314-A1 Extended Release Formulation and Methods of Treating Adrenergic Dysregulation SHIONOGI INC. 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245314-A1 Extended Release Formulation and Methods of Treating Adrenergic Dysregulation ADRB2, ADRA2A, ADRA2C ADRA2A 2/4885ADRA2B 5/4885ADRA2C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.